Trials / Completed
CompletedNCT00711191
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
A Phase 1 Dose Escalation Open Label Study Of CP-870,893 In Combination With Gemcitabine In Patients With Chemotherapy-Naïve Surgically Incurable Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy. Preliminary evidence of clinical anti-tumor activity will be sought.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | monoclonal antibody | CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles |
| DRUG | chemotherapy | gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2008-07-08
- Last updated
- 2013-12-24
- Results posted
- 2012-06-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00711191. Inclusion in this directory is not an endorsement.